<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/newamsterdam-pharma-logo-1200x675.jpg/query-dj0yMDIyMTEyODE0MTQxNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/newamsterdam-pharma-logo-1200x675.jpg/query-dj0yMDIyMTEyODE0MTQxNg"/>NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 75,117 shares of the company's stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the transaction, the chief accounting officer owned 15,000 shares of the company's stock, valued at $543,150. This trade represents a 83.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.</p><p>Louise Frederika Kooij also recently made the following trade(s): </p><ul><li>On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total value of $1,548,681.60. </li><li>On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total value of $928,072.48. </li></ul><h2>NewAmsterdam Pharma Trading Down 0.7%</h2><p>NASDAQ:NAMS opened at $35.02 on Tuesday. The stock's 50-day moving average is $37.03 and its 200-day moving average is $29.13. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $42.00. The stock has a market cap of $3.97 billion, a P/E ratio of -17.08 and a beta of 0.05. </p><hr/><hr/><p>NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million.  As a group, equities analysts forecast that  NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several brokerages recently weighed in on NAMS. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Royal Bank Of Canada increased their price target on NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, November 6th. Citigroup raised their price objective on NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 17th. The Goldman Sachs Group upped their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a &#34;neutral&#34; rating in a report on Tuesday, December 2nd. Finally, HC Wainwright initiated coverage on shares of NewAmsterdam Pharma in a report on Monday, October 20th. They set a &#34;buy&#34; rating and a $52.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has assigned  a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $45.90.</p><p><b>Get Our Latest Research Report on NAMS</b></p><h2>Institutional Investors Weigh In On NewAmsterdam Pharma</h2><p>Institutional investors and hedge funds have recently made changes to their positions in the business. OMERS ADMINISTRATION Corp increased its holdings in  NewAmsterdam Pharma by 83.9% in the first quarter. OMERS ADMINISTRATION Corp now owns 37,700 shares of the company's stock worth $772,000 after purchasing an additional 17,200 shares in the last quarter.  Trexquant Investment LP acquired a new stake in shares of  NewAmsterdam Pharma during the 1st quarter worth approximately $1,353,000.  Quarry LP bought a new stake in shares of  NewAmsterdam Pharma in the 1st quarter valued at $25,000.  Caption Management LLC increased its stake in shares of  NewAmsterdam Pharma by 341.3% in the 1st quarter. Caption Management LLC now owns 30,934 shares of the company's stock valued at $633,000 after acquiring an additional 43,756 shares in the last quarter.  Finally, Maverick Capital Ltd. lifted its position in shares of  NewAmsterdam Pharma by 57.0% during the 1st quarter. Maverick Capital Ltd. now owns 549,469 shares of the company's stock valued at $11,248,000 after acquiring an additional 199,464 shares during the period. Institutional investors own  89.89% of the company's stock. </p><h2>About NewAmsterdam Pharma</h2><p> (Get Free Report)</p><p>NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism. </p><p>The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than NewAmsterdam Pharma</li><li>Do not delete, read immediately</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Your “birthright claim” just got activated</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFNUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFNUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at NewAmsterdam Pharma?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for NewAmsterdam Pharma and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251210165310_pushainewer-14.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251210165310_pushainewer-14.jpg"/></p><div><p>Your “birthright claim” just got activated</p><p>A tiny government task force just wrapped up 20 years of work.  And buried in their federal filings, I found...</p><p><span>Behind the Markets</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjgwNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjgwNg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251221095140_pushstock-2463798640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251221095140_pushstock-2463798640.jpg"/></p><div><p>Wall Street Stockpicker Names #1 Stock of 2026</p><p>Do you own the worst stock of 2026? [Name + Ticker]  He issued warnings for RNG before it crashed 89%, BYND ...</p><p><span>Chaikin Analytics</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjgwMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjgwMQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250812113152_pushbanking-9.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250812113152_pushbanking-9.jpg"/></p><div><p>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</p><p>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)  I've been tracking a financial revolution t...</p><p><span>Investors Alley</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQ2NA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQ2NA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20251014140916_unnamed.png/query-MTc2MDQ2ODk1OTIxOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="512" height="288" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20251014140916_unnamed.png/query-MTc2MDQ2ODk1OTIxOA"/></p><div><p>End of America update</p><p>There are five truths reshaping America’s financial future — and ignoring them could be costly. From an overex...</p><p><span>Porter &amp; Company</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjc0Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjc0Ng"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://dkwegfj7whlol.cloudfront.net/copypasta/images/trump-podium-play-button.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1920" height="1080" original-src="https://imageproxy.pbkrs.com/https://dkwegfj7whlol.cloudfront.net/copypasta/images/trump-podium-play-button.jpg"/></p><div><p>The McDonald's Secret</p><p>Smart investors didn't buy road construction stocks. They asked a different question: &#34;Who benefits from all t...</p><p><span>The Oxford Club</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjY2OQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjY2OQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251126070338_pushainewer-14.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251126070338_pushainewer-14.jpg"/></p><div><p>Buy this $2 Gold Stock Before January 1, 2026</p><p>You need to own this company now - before the company’s scheduled production begins.</p><p><span>Golden Portfolio</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjU3NA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjU3NA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250916143801_pushtrumpnew-4.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250916143801_pushtrumpnew-4.jpg"/></p><div><p>“$6.6 Trillion Of Customer Bank Deposits At Risk”</p><p>The Treasury Department just issued a stunning warning:  U.S. banks could lose up to $6.6 trillion of custom...</p><p><span>Banyan Hill Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQxNw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQxNw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251223160054_pushdollar01.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251223160054_pushdollar01.jpg"/></p><div><p>The Best $1 You'll Spend This Holiday Season</p><p>Many individual traders are looking for ways to use AI tools that were once available only to large institutio...</p><p><span>Timothy Sykes</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjgzNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjgzNg"/></p></div></div></div>                     </div>                 </div></div>

NAMS

<p>NewAmsterdam Pharma's CAO, Louise Frederika Kooij, sold 75,117 shares at $36.21 each, totaling $2,719,986.57, representing an 83.35% decrease in her ownership. Following the sale, she retains 15,000 shares valued at $543,150. Kooij also sold additional shares on December 26th and 24th, totaling over $2.4 million. The stock is currently trading at $35.02, with a market cap of $3.97 billion and a P/E ratio of -17.08. Analysts have mixed ratings, with a consensus average price target of $45.90.</p>

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $2,719,986.57 in Stock